Country
Tags
- 340B_Program (1)
- 2020 (21)
- AARP (3)
- ACA (3)
- acc (1)
- Access-Innovation-Trade-off (1)
- Addiction (22)
- Affordable-Boards (1)
- Ageing (1)
- Agricultural (1)
- AI (1)
- Alex-Azar (1)
- Alexandria-Ocasio-Cortez (1)
- Allergies (1)
- ALS (1)
- Alternative-Medicine (1)
- Altitude-Sickness (1)
- Alzheimer's (3)
- Ambulances (1)
- Anti-Competition (3)
- Anti-Psychiatric (1)
- Anti-Trust (13)
- Anti-Vaccines (9)
- Anti-Vaxxers (9)
- Antibiotics (9)
- antibodie (1)
- Antibodies (4)
- API (3)
- Artemisia-annua (1)
- Asbestos (1)
- Asthma (1)
- Asymptomatic-Carriers (1)
- Bacteria (1)
- Batch-Manufacturing (1)
- BCG-Vaccine (4)
- Bernie-Sanders (14)
- Biden (20)
- Big-Data (1)
- Bill-Gates (4)
- Biohackers (5)
- Biologics (5)
- Biomarkers (1)
- Biosimilar-Adoption (1)
- Biosimilars (8)
- Biotechnology (14)
- Bipartisan-Politics (1)
- Blood-Infusions (1)
- Blood-Sugar (1)
- Bone-Regeneration (1)
- Brain-Pacemaker (1)
- Breast-Cancer (1)
- Brexit (5)
- Bribery (1)
- Bulk-Buying (5)
- Business-Development (1)
- Business-Ethics (14)
- Business-Intelligence (28)
- Buying-Power (1)
- Cancer (74)
- Cancer-Pricing (5)
- Cancer-Reimbursement (4)
- Cannabis (1)
- Cannabis-based-Medications (1)
- CAR-T (3)
- Cash-Price (1)
- CDC (4)
- Cell-Therapy (1)
- Census-Data (1)
- CF (7)
- CHAI (1)
- Chemotherapy (4)
- China-State-Medical-Insurance-Scheme (1)
- Chronic-Diseases (1)
- Clinical-Effectiveness (1)
- Clinical-Research (1)
- Clinical-Trials (6)
- Clinton-Foundation (1)
- CMS-Coverage (1)
- Co-Pays (6)
- Code-of-Conduct (21)
- Cold-Medicines (1)
- Combination-Therapy (1)
- Communicable-Diseases (1)
- Comparative-Effectiveness (7)
- Compassionate-Use (1)
- Competition (29)
- Compulsory-Licensing (1)
- Confidence-Levels (3)
- Confidential-Agreements (1)
- Conflict-of-Interest (1)
- Congress (14)
- Congressional-Hearing (14)
- Consultations (1)
- Contamination (1)
- Continuous-Manufacturing (1)
- Contraception (1)
- Contraceptives (1)
- COPD (1)
- Coronavirus (212)
- Coronavirus-Task-Force (8)
- Coronavirus-Testing (12)
- Coronavirus-Treatment (199)
- Coronavirus-Vaccine (373)
- Corporate-Taxes (1)
- Cost-Caps (1)
- Cost-Effectiveness (8)
- Cost-of-Dying (1)
- Cost-Saving (1)
- Cost-Utility (1)
- Coverage-Denial (1)
- Coverage-for-Kids (1)
- COVID-19 (360)
- COVID-19-Resurgence (1)
- COVID-Coverage (1)
- COVID-Reimbursement (1)
- COVID-Relief (4)
- COVID-Strain (9)
- COVID-Variant (3)
- Criminal-Investigations (4)
- Cross-Border (11)
- Cross-Country-Collaboration (1)
- Crowd-Funding (1)
- Curative-Therapies (1)
- Cures (1)
- Cyber-Security (1)
- Cystic-Fibrosis (13)
- Daraprim (17)
- Decriminalization (1)
- Deductibles (1)
- Defacto-Monopoly (1)
- Dengue-Fever (1)
- Depression (3)
- Dexamethasone (9)
- Diabetes (34)
- Disability (1)
- Disclosure (5)
- Discount-Cards (1)
- Dispensing-Fees (1)
- Distribution-of-Drugs (5)
- Down-Syndrome (1)
- Drug-Abuse (1)
- Drug-Adherence (1)
- Drug-Approvals (3)
- Drug-Cards (1)
- Drug-Compliance (1)
- Drug-Costs (125)
- Drug-Coupons (1)
- Drug-Coverage (8)
- Drug-Delivery (1)
- Drug-Development (22)
- Drug-Discounts (6)
- Drug-Discovery (20)
- Drug-Efficacy (3)
- Drug-formularies (1)
- Drug-Importation (20)
- Drug-Impurity (1)
- Drug-Ingredients (1)
- Drug-Innovation (22)
- Drug-Manufacturing (16)
- Drug-Overdose (29)
- Drug-Pollution (1)
- Drug-Prices (318)
- Drug-Pricing (444)
- Drug-Purchasing (1)
- Drug-Rebates (24)
- Drug-Recalls (4)
- Drug-Resistance (6)
- Drug-Shortage (16)
- Drug-Supply (12)
- Drug-Waste (3)
- DTC (28)
- Dunning-Kruger Effect (1)
- E-Cigarettes (1)
- Earnings (1)
- Elasticity-of-Pricing (1)
- Elections (19)
- Emergency-Medicine (1)
- Emergency-Use-Authorization (1)
- Emerging-Markets (36)
- Enzymes (1)
- Epidemics (6)
- Epidemiology (6)
- Epilepsy (1)
- EpiPen (13)
- EU-Commission (4)
- EU-Policy (7)
- EU-Politics (4)
- Evergreening (3)
- Evidence-Based-Medicine (1)
- evLYG (1)
- Excessive-Pricing (3)
- Executive-Order (24)
- Experimental-Payment-Models (1)
- External-Reference-Pricing (6)
- Eye-Diseases (1)
- Fair-Pricing (1)
- Fake-Cures (1)
- FDA (23)
- FDA-Approvals (3)
- FDA-Guidance (1)
- FDA-Warning (3)
- Federal-Contracts (1)
- fentanyl (13)
- Financial-Burden (1)
- fix (1)
- Focus-Protection (1)
- Food-Therapy (1)
- Formulary-Decision-Making (15)
- Fraud (3)
- Fraud-Settlements (3)
- Free-Pricing (1)
- Freeloading (1)
- Friendship-Through-Vaccinations (1)
- Gates-Foundation (4)
- Gavi-Vaccine-Alliance (5)
- Gene-Therapy (14)
- Generics (64)
- Glaucoma (1)
- Gleevec (1)
- Glivac (1)
- Global-Alliance (1)
- Global-Wealth (1)
- Growth-Drivers (1)
- Gun-Violence (1)
- H.R._3 (8)
- Hacking (4)
- HAS (1)
- HCV (6)
- HCV-Pricing (8)
- Health-Coverage (4)
- Health-Crisis (1)
- Health-Economics (15)
- Health-Humour (1)
- Health-Insurance (4)
- Health-Policy (3)
- Health-Systems (23)
- Health-Technology-Assessment (28)
- Healthcare-Costs (15)
- Healthcare-Expenditures (10)
- Healthcare-Plan (1)
- Healthcare-Pricing (5)
- Healthcare-Reform (1)
- Hemophilia (1)
- Hepatitis-C (15)
- Herd-Immunity (1)
- Heroin (4)
- HHS (15)
- hikes (1)
- Hip-Hop (1)
- HIV-AIDS (15)
- HIV-Pricing (5)
- Homemade-Drugs (1)
- Homemade-Insulin (1)
- Homeopathic-Medicine (1)
- Hospital-Bills (1)
- Hospital-Pricing (7)
- Hospitalizations (3)
- Hospitals (6)
- House-Hearing (6)
- HPV (1)
- HTA (9)
- Human-Genome (1)
- Humira (1)
- Hydroxychloroquine (10)
- ICER (9)
- Immigration (1)
- Immunity (1)
- increase (1)
- Inelasticity-of-Pricing (1)
- Inequality (1)
- Infectious-Diseases (11)
- Innovation (4)
- Insulin (115)
- Insulin-Bills (5)
- Insulin-Black-Market (1)
- Insulin-Cap (1)
- Insulin-Law (1)
- Insulin-Pricing (61)
- Insulin-Rationing (36)
- Insurance-Premiums (1)
- Intellectual-Property (1)
- International-Comparisons (13)
- International-Pricing-Index (5)
- International-Pricing-Referencing (12)
- Inversion-Deals (1)
- Investments (10)
- Investor-Relations (3)
- Kick-Backs (10)
- Know-the-Lowest-Price-Act (11)
- Kodak (1)
- Lambert-Eaton-Myasthenic-Syndrome (1)
- Launch-Pricing (5)
- Lawsuit-Settlements (15)
- Lawsuits-Litigations (55)
- Leprosy (1)
- Life-Expectancy (1)
- List-Prices (20)
- Lobbying (6)
- Lock-downs (1)
- Lomustine (1)
- Longevity (1)
- Lou-Gehrig's-Disease (1)
- LSD (1)
- Lung-Cancer (1)
- Lupus (3)
- Lyme-Disease (1)
- Malaria (7)
- Management-Consultants (1)
- Mandatory-Cuts (5)
- Mandatory-Discounts (1)
- Mandatory-Vaccinations (1)
- Market-Access (40)
- Market-Exclusivity (5)
- Market-Failure (1)
- Market-Intelligence (30)
- Medicaid (4)
- Medicaid-Negotiations (1)
- Medical-Bills (1)
- Medical-Devices (5)
- Medical-Ethics (6)
- Medical-Failures (1)
- Medical-History (4)
- Medical-Implants (5)
- Medical-Liability (1)
- Medical-Malpractice (1)
- Medical-Marijuana (1)
- Medical-Marketing (7)
- Medical-Practice (1)
- Medical-Robots (1)
- Medicare (20)
- Medicare-for-all (13)
- Medicare-Negotiations (9)
- Melanoma (1)
- Mental-Disorders (1)
- Mental-Ilness (5)
- Mergers-Acqusitions (6)
- MERS (1)
- Micro-dosing (1)
- Microrobots (1)
- Middle-Men (1)
- Midterms (6)
- Migraine (3)
- Moles (1)
- Moral-Failure (1)
- Mortality (1)
- Most-Favored-Customer (1)
- Most-Favoured-Nation (7)
- x mRNA-Vaccines (2)
- Multi-Drug-Resistant (1)
- Multiple-Sclerosis (3)
- NAFTA (8)
- Naloxone (4)
- Narcolepsy (1)
- National-Medical-Insurance-Catalogue (1)
- National-Pharmacare (13)
- National-Pride (1)
- Natural-Medicines (1)
- NCDs (1)
- Netflix-Model (7)
- NHS (31)
- NHS-Scotland (1)
- NICE (19)
- Non-Communicable-Diseases (1)
- Non-Medical-Switching (1)
- Nutrition-Science (1)
- Obamacare (9)
- Obesity (1)
- Off-Label (5)
- Off-Patent (3)
- Off-shore (1)
- Oncology (1)
- Online-Pharmacies (1)
- Operation-Moonshot (1)
- Opioid-Tax (1)
- Opioids (161)
- Orkambi (4)
- Orphan-Drug-Act (1)
- Orphan-Drugs (20)
- Out-of-Pocket (7)
- Outcomes-Based-Pricing (1)
- Outcomes-Research (1)
- Over-Prescribing (1)
- Overpayments (1)
- OxyContin (29)
- Pain (1)
- Pain-Management (1)
- Pandemic-Pricing (1)
- Pandemics (9)
- Panic-Buying (3)
- Patent-Cliff (1)
- Patent-Protection (19)
- Patents (11)
- Patient-Access (178)
- Patient-Advocacy (4)
- Patient-Affordability (23)
- Patient-Charities (1)
- Patient-Costs (4)
- patient-outcomes (5)
- Patient-Safety (13)
- Pay-for-Delay (4)
- Pay-For-Performance (5)
- PBMs (28)
- PBS (3)
- PCSK9-inhibitors (1)
- Pediatrics (1)
- Penalties-Fines (4)
- Penicillin (1)
- Personal-Importation (20)
- Personalized-Medicine (1)
- Pharma-Bro (4)
- Pharma-Influence (10)
- Pharmaceuticals (6)
- Pharmacists (4)
- Pharmacoeconomics (4)
- Pharmacy-Benefits-Managers (43)
- Pharmacy-Prices (1)
- PhRMA (1)
- PKU (1)
- Plans-for-Kids (1)
- PMPRB (9)
- Pneumonia (1)
- Police (1)
- Policy (3)
- Polio (3)
- Political-Pressure (1)
- Postpartum-Depression (1)
- PPE (1)
- Pragmatic-Trials (1)
- Pre-Existing (1)
- Presidential-Race (11)
- Price-Caps (4)
- Price-Ceilings (1)
- Price-Controls (17)
- Price-Cuts (9)
- Price-Decreases (1)
- Price-Fixing (10)
- Price-gouging (30)
- Price-Hikes (92)
- Price-Increases (44)
- Price-Inflation (4)
- Price-Negotiations (13)
- Price-Regulations (22)
- Price-Transparency (30)
- Pricing-Bills (29)
- Pricing-Blueprint (24)
- Pricing-Board (3)
- Pricing-Caps (10)
- Pricing-Legislation (49)
- Pricing-Negotiations (3)
- Pricing-Pledges (1)
- Pricing-Probe (1)
- Pricing-Reform (10)
- Pricing-Strategy (1)
- Pricing-Task-Force (1)
- Pricing_Collusion (9)
- Prior-Authorization (3)
- Priority-R&D (1)
- Priority-Review-Voucher (1)
- Private-Health-Insurance (1)
- Production-Logistics (13)
- Profiteering (3)
- Profits-Revenues (3)
- Prostate-Cancer (1)
- Protests (1)
- Provincial-Access (3)
- Provincial-Level (1)
- Prozac (1)
- Psychiatrics (1)
- Public-Expenditures (1)
- Public-Funding (5)
- Public-Health (47)
- Public-Inquiry (1)
- Public-Opinion (12)
- Public-Policy (4)
- Public-Relations (1)
- Public-Shaming (1)
- Public-Trust (11)
- Purdue-Pharma (40)
- Quality-of-Life (1)
- R&D (14)
- Rabies (1)
- Racial-Disparity (1)
- Racial-Diversity (1)
- Radiotherapy (1)
- Rare-Diseases (26)
- Re-Purposed (1)
- Real-World-Data (4)
- Real-World-Evidence (6)
- Rebate-Wall (1)
- Reference-based-Pricing (1)
- Reference-Pricing (9)
- Regulatory-Affairs (4)
- Rehab (1)
- Reimbursement (7)
- Reimportation (5)
- Relief-Bill (3)
- Remdesivir (37)
- Reputation (1)
- Respirators (1)
- Respiratory-Disease (3)
- Response-Based-Pricing (1)
- Right-to-Try (3)
- Robitussin (1)
- roll (1)
- Sackler-Family (28)
- Safety-Standards (9)
- Saliva-Testing (1)
- Senate-Bills (1)
- Senate-Hearings (20)
- Shkreli (11)
- Single-Payer (21)
- Skin-Care (1)
- Skin-Products (1)
- Skin-Whitening-Products (1)
- SMA (3)
- Social-Spending (1)
- Socialism (1)
- Socialized-Medicine (1)
- Socioeconomic-Impact (1)
- SOTU (5)
- Sovaldi (3)
- Specialty-Drugs (4)
- Spinal-Muscular-Atrophy (7)
- Spinraza (4)
- State-Attorney-General (1)
- State-level (110)
- State-of-Emergency (1)
- Step-Therapy (3)
- Still-Births (1)
- Stimulus-Bill (1)
- Strategic-Pricing (1)
- Supply-Chain (9)
- Supply-side-Policies (1)
- Surprise-Billing (1)
- Sweet-Wormwood (1)
- Take-Back-Program (1)
- Talc-based-Products (1)
- Targeted-Therapy (1)
- Tariffs (3)
- Tax-Credits (3)
- Tax-Evasion (1)
- Tax-Heaven (1)
- Taxes (1)
- TB (4)
- Tele-Medicine (1)
- Thalidomide (3)
- Tobacco (1)
- Trade (22)
- Trans-Pacific-Partnership (1)
- Transportation (1)
- Treatment-Cost (3)
- trum (1)
- Trump (227)
- Trump (379 (3)
- Tuberculosis (3)
- TV-Ads (30)
- Tylenol (1)
- Typhoid-Fever (1)
- UHC (1)
- UK-Politics (6)
- United-Nations (1)
- Universal-Healthcare (20)
- US-Insurers (59)
- US-Pharmacies (1)
- US-Policy (59)
- US-Politics (154)
- US-Senate (1)
- USMCA (9)
- Vaccinations (35)
- Vaccine-Access (11)
- Vaccine-Approvals (1)
- Vaccine-Deal (5)
- Vaccine-Deaths (1)
- Vaccine-Diplomacy (11)
- Vaccine-Distribution (37)
- Vaccine-Efficacy (3)
- Vaccine-Exports (1)
- Vaccine-Inequality (1)
- Vaccine-Manufacturing (1)
- Vaccine-Nationalism (7)
- Vaccine-Passport (3)
- Vaccine-Pricing (11)
- Vaccine-Rollout (30)
- Vaccine-Shortage (1)
- Vaccine-Supply (21)
- Vaccines (274)
- Valsartan (1)
- Value-based Contracts (6)
- Value-based Payment (12)
- Value-based Pricing (32)
- Value-in-Health (9)
- Value-of-Medicines (3)
- Veterans-Affairs (1)
- Vincristine (5)
- Viral-Mutations (7)
- Viral-Strain (9)
- Viruses (1)
- Vitamin-C (1)
- Vitamins (1)
- Voluntary-Drops (1)
- Vulnerability (1)
- Wal-Mart (1)
- Wall-St (4)
- War-on-Drugs (1)
- Warren-Buffett (1)
- Washington-DC (1)
- White-House (1)
- WHO (13)
- Women-in-Health (1)
- Zantac (3)
- Zolgensma (6)
Videos
close
- Reset All Filters
- 2 results found
- x mRNA-Vaccines
-
Coronavirus mRNA Vaccine Safety and Efficacy
Millions of people are now being immunized with mRNA vaccines from Pfizer-BioNTech and Moderna. Both vaccines have very high efficacy and look safe in the short-term. -
mRNA Vaccines for COVID-19
The use of messenger RNA (mRNA) in medical interventions has been researched for the last 20 years, including in vaccines hoping to fight diseases such as cancer, rabies, Ebola and the Zika virus.Comments
No comments yet. Create an account and log in to post a comment.
Comments